Uh Cleveland Medical Center
- Type
- Teaching hospital
- Where
- Cleveland, OH
- Medicare CCN
- 360137
- Received
- $10,612,982 in 1,682 records, 2023 ($1,229,738 general, $9,383,243 research)
- Source
- CMS Open Payments search ↗
On this site
- Patent assignee: UH Cleveland Medical Center Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2023 | General payment | 138 | $1,229,738 |
| 2023 | Research payment | 1,544 | $9,383,243 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 1,544 | $9,383,243 |
| Grant | 24 | $583,911 |
| Space rental or facility fees (teaching hospital only) | 47 | $206,081 |
| Charitable Contribution | 2 | $192,500 |
| Consulting Fee | 18 | $156,049 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 34 | $30,035 |
| Royalty or License | 3 | $22,507 |
| Education | 1 | $20,000 |
| Debt forgiveness | 2 | $14,095 |
| Long term medical supply or device loan | 7 | $4,560 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2023-12-31 | Gilead Sciences, Inc. | $398,566 | Grant | Cash or cash equivalent | 2023 | ||
| 2023-12-31 | Merck Sharp & Dohme LLC | $198,327 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Phase I,II study of laser interstitial thermotherapy LITT combined with checkpoint inhibitor for recurrent GBM | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $145,540 | Research payment | Cash or cash equivalent | Biological, CARDIOVASCULAR | A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept versus Placebo for | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $57,720 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy vers | 2023 |
| 2023-12-31 | Siemens Medical Solutions USA, Inc. | $54,246 | Research payment | In-kind items and services | TrueBeam Device, Oncology | A Prospective Imaging Study of Target Definition and Radiation Planning Workflows on the Integrated TrueBeam-HyperSight | 2023 |
| 2023-12-31 | Mannkind Corporation | $28,763 | Research payment | Cash or cash equivalent | AFREZZA Drug, DIABETES MEDICINE | INHALE-1 | 2023 |
| 2023-12-31 | Siemens Medical Solutions USA, Inc. | $25,800 | Research payment | In-kind items and services | Evaluation of AIRC Brain Morphometry | 2023 | |
| 2023-12-31 | Merck Sharp & Dohme LLC | $18,609 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $18,252 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-79 | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $6,252 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-blind Study of Pembrolizumab MK-3475 Plus Docetaxel Plus Prednisone versus Placebo Plus Do | 2023 |
| 2023-12-31 | Medtronic, Inc. | $4,371 | Research payment | In-kind items and services | CIP337 SUCCEED | 2023 | |
| 2023-12-31 | Merck Sharp & Dohme LLC | $3,791 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $3,483 | Research payment | In-kind items and services | Biological, CARDIOVASCULAR | A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept versus Placebo for | 2023 |
| 2023-12-31 | Stryker Corporation | $1,231 | Long term medical supply or device loan | In-kind items and services | REMB Device, SURGICAL | 2023 | |
| 2023-12-31 | ABBVIE INC. | $1,220 | Research payment | In-kind items and services | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously | 2023 | |
| 2023-12-31 | Merck Sharp & Dohme LLC | $1,102 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Pembrolizumab in Combination with Cisplatin a | 2023 |
| 2023-12-31 | ABBVIE INC. | $875 | Research payment | In-kind items and services | A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Sma | 2023 | |
| 2023-12-31 | Stryker Corporation | $799 | Long term medical supply or device loan | In-kind items and services | REMB Device, SURGICAL | 2023 | |
| 2023-12-31 | Stryker Corporation | $799 | Long term medical supply or device loan | In-kind items and services | REMB Device, SURGICAL | 2023 | |
| 2023-12-31 | Stryker Corporation | $799 | Long term medical supply or device loan | In-kind items and services | REMB Device, SURGICAL | 2023 | |
| 2023-12-31 | Stryker Corporation | $799 | Long term medical supply or device loan | In-kind items and services | REMB Device, SURGICAL | 2023 | |
| 2023-12-31 | Merck KGaA | $689 | Research payment | Cash or cash equivalent | TEPMETKO Drug, Oncology | A randomized, double-blind placebo-controlled, Phase 3 study of Debio 1143 in combination with platinum-based chemothera | 2023 |
| 2023-12-31 | ABBVIE INC. | $687 | Research payment | In-kind items and services | LINZESS Drug, GASTROENTEROLOGY | A Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Safety and Efficacy Study of Linaclotide Versus Placeb | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $435 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $204 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-79 | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $158 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase II Clinical Trial of Single Agent Pembrolizumab MK-3475 in Subjects with Recurrent or Metastatic Head and Neck S | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $157 | Research payment | In-kind items and services | NOXAFIL Drug, INFECTIOUS DISEASE | Phase IB study of the Safety, Tolerance, and Pharmacokinetics of Oral Posaconazole in Immunocompromised Children with Ne | 2023 |
| 2023-12-31 | ABBVIE INC. | $94 | Research payment | In-kind items and services | A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumor | 2023 | |
| 2023-12-31 | ABBVIE INC. | $88 | Research payment | In-kind items and services | BOTOX Biological, FACIAL AESTHETICS | Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Inte | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $78 | Research payment | In-kind items and services | NOXAFIL Drug, INFECTIOUS DISEASE | A Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous IV and Powder for Oral Suspension Formulations | 2023 |
| 2023-12-31 | ABBVIE INC. | $58 | Research payment | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatri | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $51 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized Open-Label Phase III Study of Single Agent Pembrolizumab versus Single Agent Chemotherapy per Physician s C | 2023 |
| 2023-12-31 | Fisher & Paykel Healthcare Inc | $23 | Long term medical supply or device loan | In-kind items and services | FISHER & PAYKEL HEALTHCARE Device, Heated respiratory humidifier | 2023 | |
| 2023-12-31 | Merck Sharp & Dohme LLC | $14 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 2, Randomized, Double-Blind Study of Pembrolizumab MK-3475 plus Epacadostat INCB024360 Versus Pembrolizumab plus | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $6 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III Randomized Clinical Trial of Pembrolizumab MK-3475 versus Paclitaxel, Docetaxel or Vinflunine in Subjects wi | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $4 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A phase III study of Lenalidomide and low-dose Dexamethasone with or without Pembrolizumab MK3475 in newly diagnosed and | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $0 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase II Study of Pembrolizumab Monotherapy in Third-line Previously Treated Subjects with Advanced,Metastatic Adenoca | 2023 |
| 2023-12-29 | Cochlear Americas | $812 | Research payment | Cash or cash equivalent | OSIA OSI300 IMPLANT Device, Implantable hearing solution | Osia 2 System in a pediatric expansion study | 2023 |
| 2023-12-29 | ARGENX US, INC. | $40 | Research payment | In-kind items and services | VYVGART HYTRULO Drug, Immunology | A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and the Safety of | 2023 |
| 2023-12-28 | ABBVIE INC. | $12,860 | Research payment | Cash or cash equivalent | ORILISSA Drug, WOMENS HEALTH | A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-A | 2023 |
| 2023-12-28 | Medtronic, Inc. | $500 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | Low Risk Bicuspid | 2023 |
| 2023-12-28 | Medtronic, Inc. | $500 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | Low Risk Bicuspid | 2023 |
| 2023-12-26 | ABBVIE INC. | $250 | Research payment | Cash or cash equivalent | BOTOX Biological, FACIAL AESTHETICS | Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Inte | 2023 |
| 2023-12-25 | Johnson & Johnson Vision Care, Inc. | $47,847 | Research payment | Cash or cash equivalent | Vision Performance of a Soft Contact Lens with Myopia Control Optics in a Pediatric Population | 2023 | |
| 2023-12-22 | AstraZeneca Pharmaceuticals LP | $40,180 | Research payment | Cash or cash equivalent | A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigato | 2023 | |
| 2023-12-22 | Cochlear Americas | $883 | Research payment | Cash or cash equivalent | Cochlear Implant With Dexamethasone Eluting Electrode Array | 2023 | |
| 2023-12-21 | ABBVIE INC. | $3,050 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously | 2023 | |
| 2023-12-21 | ABBVIE INC. | $2,866 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously | 2023 | |
| 2023-12-21 | ABBVIE INC. | $1,708 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously | 2023 | |
| 2023-12-21 | ABBVIE INC. | $1,373 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously | 2023 | |
| 2023-12-21 | ABBVIE INC. | $1,373 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously | 2023 | |
| 2023-12-21 | ABBVIE INC. | $1,373 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously | 2023 | |
| 2023-12-21 | ABBVIE INC. | $1,170 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously | 2023 | |
| 2023-12-21 | ABBVIE INC. | $1,170 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously | 2023 | |
| 2023-12-21 | ABBVIE INC. | $617 | Research payment | Cash or cash equivalent | BOTOX Biological, FACIAL AESTHETICS | Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Inte | 2023 |
| 2023-12-21 | Medtronic, Inc. | $538 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2023 |
| 2023-12-21 | ABBVIE INC. | $466 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously | 2023 | |
| 2023-12-21 | ABBVIE INC. | $466 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously | 2023 | |
| 2023-12-21 | ABBVIE INC. | $466 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously | 2023 | |
| 2023-12-21 | ABBVIE INC. | $466 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously | 2023 | |
| 2023-12-21 | ABBVIE INC. | $466 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously | 2023 | |
| 2023-12-21 | ABBVIE INC. | $466 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously | 2023 | |
| 2023-12-21 | ABBVIE INC. | $466 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously | 2023 | |
| 2023-12-21 | ABBVIE INC. | $466 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously | 2023 | |
| 2023-12-21 | ABBVIE INC. | $466 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously | 2023 | |
| 2023-12-21 | ABBVIE INC. | $466 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously | 2023 | |
| 2023-12-21 | ABBVIE INC. | $466 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously | 2023 | |
| 2023-12-21 | ABBVIE INC. | $466 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously | 2023 | |
| 2023-12-21 | ABBVIE INC. | $466 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously | 2023 | |
| 2023-12-21 | ABBVIE INC. | $466 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously | 2023 | |
| 2023-12-21 | ABBVIE INC. | $466 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously | 2023 | |
| 2023-12-21 | ABBVIE INC. | $466 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously | 2023 | |
| 2023-12-21 | ABBVIE INC. | $466 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously | 2023 | |
| 2023-12-21 | ABBVIE INC. | $466 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously | 2023 | |
| 2023-12-21 | ABBVIE INC. | $466 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously | 2023 | |
| 2023-12-21 | ABBVIE INC. | $466 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously | 2023 | |
| 2023-12-21 | ABBVIE INC. | $466 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously | 2023 | |
| 2023-12-21 | ABBVIE INC. | $466 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously | 2023 | |
| 2023-12-21 | ABBVIE INC. | $466 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously | 2023 | |
| 2023-12-21 | ABBVIE INC. | $466 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously | 2023 | |
| 2023-12-21 | ABBVIE INC. | $466 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously | 2023 | |
| 2023-12-21 | ABBVIE INC. | $466 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously | 2023 | |
| 2023-12-21 | ABBVIE INC. | $466 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously | 2023 | |
| 2023-12-21 | ABBVIE INC. | $466 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously | 2023 | |
| 2023-12-21 | ABBVIE INC. | $466 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously | 2023 | |
| 2023-12-21 | ABBVIE INC. | $466 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously | 2023 | |
| 2023-12-21 | ABBVIE INC. | $466 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously | 2023 | |
| 2023-12-21 | ABBVIE INC. | $466 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously | 2023 | |
| 2023-12-21 | ABBVIE INC. | $466 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously | 2023 | |
| 2023-12-21 | ABBVIE INC. | $466 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously | 2023 | |
| 2023-12-21 | ABBVIE INC. | $466 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously | 2023 | |
| 2023-12-21 | ABBVIE INC. | $466 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously | 2023 | |
| 2023-12-21 | ABBVIE INC. | $466 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously | 2023 | |
| 2023-12-21 | ABBVIE INC. | $466 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously | 2023 | |
| 2023-12-21 | ABBVIE INC. | $466 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously | 2023 | |
| 2023-12-21 | ABBVIE INC. | $466 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously | 2023 | |
| 2023-12-21 | ABBVIE INC. | $466 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously | 2023 | |
| 2023-12-21 | ABBVIE INC. | $466 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously | 2023 | |
| 2023-12-21 | ABBVIE INC. | $466 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously | 2023 | |
| 2023-12-20 | SEAGEN INC. | $9,065 | Research payment | Cash or cash equivalent | A Phase 1 Study of SEA-CD70 in Myeloid Malignancies | 2023 | |
| 2023-12-20 | SEAGEN INC. | $4,565 | Research payment | Cash or cash equivalent | A Phase 1 Study of SEA-CD70 in Myeloid Malignancies | 2023 | |
| 2023-12-20 | SEAGEN INC. | $2,250 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer | 2023 |
| 2023-12-20 | ABBVIE INC. | $1,250 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administer | 2023 | |
| 2023-12-20 | Glaukos Corporation | $810 | Research payment | Cash or cash equivalent | iStent inject Trabecular Micro-Bypass System Model G2-M-IS Device, Glaucoma | iStent Inject Trabecular Micro-Bypass System New Enrollment Post-Approval Study | 2023 |
| 2023-12-20 | Glaukos Corporation | $630 | Research payment | Cash or cash equivalent | iStent inject Trabecular Micro-Bypass System Model G2-M-IS Device, Glaucoma | iStent Inject Trabecular Micro-Bypass System New Enrollment Post-Approval Study | 2023 |
| 2023-12-20 | Abbott Laboratories | $500 | Research payment | Cash or cash equivalent | CARDIOMEMS Device, Heart Failure | Hemodynamic-GUIDEd Management of Heart Failure | 2023 |
| 2023-12-20 | Glaukos Corporation | $280 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | iDose TR Drug, Glaucoma | 2023 | |
| 2023-12-20 | Glaukos Corporation | $270 | Research payment | Cash or cash equivalent | iStent inject Trabecular Micro-Bypass System Model G2-M-IS Device, Glaucoma | iStent Inject Trabecular Micro-Bypass System New Enrollment Post-Approval Study | 2023 |
| 2023-12-20 | Glaukos Corporation | $230 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | iDose TR Drug, Glaucoma | 2023 | |
| 2023-12-20 | SEAGEN INC. | $200 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer | 2023 |
| 2023-12-20 | Glaukos Corporation | $180 | Research payment | Cash or cash equivalent | iStent inject Trabecular Micro-Bypass System Model G2-M-IS Device, Glaucoma | iStent Inject Trabecular Micro-Bypass System New Enrollment Post-Approval Study | 2023 |
| 2023-12-20 | Glaukos Corporation | $180 | Research payment | Cash or cash equivalent | IDOSE TR Drug, Glaucoma | Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophtha | 2023 |
| 2023-12-20 | Glaukos Corporation | $180 | Research payment | Cash or cash equivalent | iStent inject Trabecular Micro-Bypass System Model G2-M-IS Device, Glaucoma | iStent Inject Trabecular Micro-Bypass System New Enrollment Post-Approval Study | 2023 |
| 2023-12-20 | Glaukos Corporation | $90 | Research payment | Cash or cash equivalent | iStent inject Trabecular Micro-Bypass System Model G2-M-IS Device, Glaucoma | iStent Inject Trabecular Micro-Bypass System New Enrollment Post-Approval Study | 2023 |
| 2023-12-20 | Glaukos Corporation | $90 | Research payment | Cash or cash equivalent | IDOSE TR Drug, Glaucoma | Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophtha | 2023 |
| 2023-12-20 | Glaukos Corporation | $90 | Research payment | Cash or cash equivalent | IDOSE TR Drug, Glaucoma | Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophtha | 2023 |
| 2023-12-20 | Glaukos Corporation | $90 | Research payment | Cash or cash equivalent | IDOSE TR Drug, Glaucoma | Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophtha | 2023 |
| 2023-12-20 | Glaukos Corporation | $90 | Research payment | Cash or cash equivalent | iStent inject Trabecular Micro-Bypass System Model G2-M-IS Device, Glaucoma | iStent Inject Trabecular Micro-Bypass System New Enrollment Post-Approval Study | 2023 |
| 2023-12-20 | Glaukos Corporation | $90 | Research payment | Cash or cash equivalent | IDOSE TR Drug, Glaucoma | Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophtha | 2023 |
| 2023-12-20 | Glaukos Corporation | $90 | Research payment | Cash or cash equivalent | iStent inject Trabecular Micro-Bypass System Model G2-M-IS Device, Glaucoma | iStent Inject Trabecular Micro-Bypass System New Enrollment Post-Approval Study | 2023 |
| 2023-12-20 | Glaukos Corporation | $90 | Research payment | Cash or cash equivalent | IDOSE TR Drug, Glaucoma | Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophtha | 2023 |
| 2023-12-20 | Glaukos Corporation | $90 | Research payment | Cash or cash equivalent | IDOSE TR Drug, Glaucoma | Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophtha | 2023 |
| 2023-12-19 | ARGENX US, INC. | $2,900 | Research payment | Cash or cash equivalent | VYVGART HYTRULO Drug, Immunology | An Open-Label, Multicenter, Follow-up Trial of ARGX-113-1904 to Evaluate the Safety, Tolerability, and Efficacy of Efgar | 2023 |
| 2023-12-19 | Travere Therapeutics, Inc. | $2,047 | Research payment | Cash or cash equivalent | 021IGAN17001 | 2023 | |
| 2023-12-19 | ARGENX US, INC. | $1,000 | Research payment | Cash or cash equivalent | VYVGART HYTRULO Drug, Immunology | An Open-Label, Multicenter, Follow-up Trial of ARGX-113-1904 to Evaluate the Safety, Tolerability, and Efficacy of Efgar | 2023 |
| 2023-12-19 | Saluda Medical Americas, Inc. | $907 | Research payment | Cash or cash equivalent | Evoke SCS Device, Spinal Cord Stimulation | ECAP Study | 2023 |
| 2023-12-19 | Regeneron Pharmaceuticals, Inc. | $558 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFECT OF DUPILUMAB ON EXERCISE CAP | 2023 |
| 2023-12-19 | ARGENX US, INC. | $500 | Research payment | Cash or cash equivalent | VYVGART HYTRULO Drug, Immunology | An Open-Label, Multicenter, Follow-up Trial of ARGX-113-1904 to Evaluate the Safety, Tolerability, and Efficacy of Efgar | 2023 |
| 2023-12-18 | Boston Scientific Corporation | $11,095 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product IC | ACURATE IDE | 2023 |
| 2023-12-18 | GENZYME CORPORATION | $6,741 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-12-18 | Boston Scientific Corporation | $750 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product IC | CHAMPION AF | 2023 |
| 2023-12-15 | ABBVIE INC. | $15,680 | Research payment | Cash or cash equivalent | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Ind | 2023 | |
| 2023-12-15 | Baxter Healthcare | $14,080 | Debt forgiveness | In-kind items and services | Device, Trauma (Emergency, Injury, Surgery) | 2023 | |
| 2023-12-15 | ABBVIE INC. | $9,800 | Research payment | Cash or cash equivalent | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Ind | 2023 | |
| 2023-12-15 | Abbott Laboratories | $4,000 | Research payment | Cash or cash equivalent | XIENCE V Device, Vascular | Optical Coherence Tomography (OCT) Guided Coronary Stent Implantation Compared to Angiography: a Multicenter Randomized | 2023 |
| 2023-12-15 | ABBVIE INC. | $3,500 | Research payment | Cash or cash equivalent | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Ind | 2023 | |
| 2023-12-15 | Janssen Research & Development, LLC | $3,000 | Research payment | Cash or cash equivalent | A Randomized, Stratified, Double-blind, Placebo-Controlled Study to Investigate the Efficacy, Safety and Tolerability of | 2023 | |
| 2023-12-15 | Janssen Research & Development, LLC | $3,000 | Research payment | Cash or cash equivalent | A Randomized, Stratified, Double-blind, Placebo-Controlled Study to Investigate the Efficacy, Safety and Tolerability of | 2023 | |
| 2023-12-15 | ABBVIE INC. | $2,800 | Research payment | Cash or cash equivalent | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Ind | 2023 | |
| 2023-12-15 | ABBVIE INC. | $2,800 | Research payment | Cash or cash equivalent | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Ind | 2023 | |
| 2023-12-15 | Abbott Laboratories | $750 | Research payment | Cash or cash equivalent | ESPRIT Device, Vascular | LIFE-BTK (Pivotal Investigation of Safety and Efficacy of BRS Treatment-Below The Knee) Randomized Controlled Trial | 2023 |
| 2023-12-14 | Siemens Medical Solutions USA, Inc. | $10,404 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2023 | ||
| 2023-12-14 | ABBVIE INC. | $3,213 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously | 2023 | |
| 2023-12-14 | ABBVIE INC. | $2,572 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously | 2023 | |
| 2023-12-14 | ABBVIE INC. | $2,177 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously | 2023 | |
| 2023-12-14 | ABBVIE INC. | $1,708 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously | 2023 | |
| 2023-12-14 | ABBVIE INC. | $1,170 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously | 2023 | |
| 2023-12-14 | ABBVIE INC. | $900 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously | 2023 | |
| 2023-12-14 | ABBVIE INC. | $900 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously | 2023 | |
| 2023-12-14 | Alcon Research LLC | $660 | Research payment | Cash or cash equivalent | HYDRUS Microstent Device, Ophthalmology | The Hydrus Microstent New Enrollment Post-Approval Study: A Prospective, Non-Randomized, Multicenter, Single Arm Clinica | 2023 |
| 2023-12-14 | ABBVIE INC. | $220 | Research payment | Cash or cash equivalent | ORILISSA Drug, WOMENS HEALTH | Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea R | 2023 |
| 2023-12-13 | Roche Products Limited | $15,686 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | Morpheus UC | 2023 |
| 2023-12-12 | Siemens Medical Solutions USA, Inc. | $34,685 | Research payment | Cash or cash equivalent | TrueBeam Device, Oncology | A Prospective Imaging Study of Target Definition and Radiation Planning Workflows on the Integrated TrueBeam-HyperSight | 2023 |
| 2023-12-12 | Regeneron Healthcare Solutions, Inc. | $1,000 | Grant | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | 2023 | |
| 2023-12-12 | Cochlear Americas | $65 | Research payment | Cash or cash equivalent | COCHLEAR NUCLEUS CI632 COCHLEAR IMPLANT WITH SLIM MODIOLAR ELECTRODE Device, Implantable hearing solution | Perimodiolar Implant Performance in Adults with Low-Frequency Residual Hearing | 2023 |
| 2023-12-11 | ABBVIE INC. | $3,050 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously | 2023 | |
| 2023-12-11 | ABBVIE INC. | $3,013 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously | 2023 | |
| 2023-12-11 | ABBVIE INC. | $3,013 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously | 2023 | |
| 2023-12-11 | Johnson & Johnson Surgical Vision, Inc. | $2,890 | Research payment | Cash or cash equivalent | VSCO-110-LOKE_Cornea Image Analysis Reading Center | 2023 | |
| 2023-12-11 | Johnson & Johnson Surgical Vision, Inc. | $2,890 | Research payment | Cash or cash equivalent | VSCO-110-LOKE_Cornea Image Analysis Reading Center | 2023 | |
| 2023-12-11 | ABBVIE INC. | $2,275 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously | 2023 | |
| 2023-12-11 | ABBVIE INC. | $1,708 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously | 2023 | |
| 2023-12-11 | ABBVIE INC. | $1,373 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously | 2023 | |
| 2023-12-11 | ABBVIE INC. | $1,373 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously | 2023 | |
| 2023-12-11 | Cochlear Americas | $883 | Research payment | Cash or cash equivalent | Cochlear Implant With Dexamethasone Eluting Electrode Array | 2023 | |
| 2023-12-11 | GENZYME CORPORATION | $238 | Research payment | Cash or cash equivalent | ATLAS-PEDS: An Open-label, Multinational Study of Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 1 | 2023 | |
| 2023-12-08 | Stryker Corporation | $33,150 | Research payment | Cash or cash equivalent | T2 Device, TRAUMA & EXTREMETIES | A RETROSPECTIVE DATA COLLECTION OF THE TREATMENT OF FEMORAL FRACTURES WITH THE T2 ALPHA FEMUR RETROGRADE NAILING SYSTEM | 2023 |
| 2023-12-08 | Regeneron Pharmaceuticals, Inc. | $3,500 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN PEDIATRIC PA | 2023 |
| 2023-12-08 | Regeneron Pharmaceuticals, Inc. | $2,500 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN PEDIATRIC PA | 2023 |
| 2023-12-08 | Ipsen Pharma SAS | $2,276 | Research payment | Cash or cash equivalent | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Saf | 2023 | |
| 2023-12-08 | Takeda Pharmaceuticals U.S.A., Inc. | $2,000 | Research payment | Cash or cash equivalent | A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATR | 2023 | |
| 2023-12-08 | Takeda Pharmaceuticals U.S.A., Inc. | $1,500 | Research payment | Cash or cash equivalent | A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATR | 2023 | |
| 2023-12-08 | Takeda Pharmaceuticals U.S.A., Inc. | $1,500 | Research payment | Cash or cash equivalent | A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATR | 2023 | |
| 2023-12-08 | Takeda Pharmaceuticals U.S.A., Inc. | $1,250 | Research payment | Cash or cash equivalent | A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATR | 2023 | |
| 2023-12-08 | Cochlear Americas | $1,141 | Research payment | Cash or cash equivalent | COCHLEAR NUCLEUS CI632 COCHLEAR IMPLANT WITH SLIM MODIOLAR ELECTRODE Device, Implantable hearing solution | Perimodiolar Implant Performance in Adults with Low-Frequency Residual Hearing | 2023 |
| 2023-12-08 | Regeneron Pharmaceuticals, Inc. | $1,000 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN PEDIATRIC PA | 2023 |
| 2023-12-08 | Takeda Pharmaceuticals U.S.A., Inc. | $1,000 | Research payment | Cash or cash equivalent | A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATR | 2023 | |
| 2023-12-08 | Takeda Pharmaceuticals U.S.A., Inc. | $975 | Research payment | Cash or cash equivalent | A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATR | 2023 | |
| 2023-12-08 | Cochlear Americas | $883 | Research payment | Cash or cash equivalent | Cochlear Implant With Dexamethasone Eluting Electrode Array | 2023 | |
| 2023-12-08 | Takeda Pharmaceuticals U.S.A., Inc. | $600 | Research payment | Cash or cash equivalent | A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATR | 2023 | |
| 2023-12-08 | Takeda Pharmaceuticals U.S.A., Inc. | $500 | Research payment | Cash or cash equivalent | A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATR | 2023 | |
| 2023-12-07 | ABBVIE INC. | $25,312 | Research payment | Cash or cash equivalent | A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Sma | 2023 | |
| 2023-12-07 | ABBVIE INC. | $10,364 | Research payment | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allog | 2023 |
| 2023-12-07 | Ethicon Inc. | $7,565 | Research payment | Cash or cash equivalent | A Post Approval Study of the LINX Reflux Management System | 2023 | |
| 2023-12-07 | Ethicon Inc. | $3,210 | Research payment | Cash or cash equivalent | A Prospective Multi Center Study of Reflux Management with the LINX System for Gastroesophageal REFlux Disease after Lap | 2023 | |
| 2023-12-07 | ABBVIE INC. | $2,209 | Research payment | Cash or cash equivalent | A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and or Refractory Solid Tumor | 2023 | |
| 2023-12-07 | Genmab U.S., Inc. | $874 | Research payment | Cash or cash equivalent | First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With | 2023 | |
| 2023-12-07 | Medtronic, Inc. | $350 | Research payment | Cash or cash equivalent | SYMPLICITY G3 Device, Renal Denervation System | SPYRAL HTN-ON MED Expan | 2023 |
| 2023-12-06 | SEAGEN INC. | $6,913 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer | 2023 |
| 2023-12-06 | SEAGEN INC. | $5,000 | Research payment | Cash or cash equivalent | A Platform Study Master Protocol to Evaluate the Antitumor Activity and Safety of Targeted Therapeutic Agents in Subject | 2023 | |
| 2023-12-06 | Centinel Spine, LLC | $4,032 | Research payment | Cash or cash equivalent | PRODISC C SK Device, Spine Implant | A Multicenter, Prospective, Randomized, Controlled Trial Comparing the Safety and Effectiveness of Prodisc C SK and Prod | 2023 |
| 2023-12-06 | Bolton Medical Inc | $3,360 | Research payment | Cash or cash equivalent | RELAY THORACIC STENT-GRAFT WITH PLUS DELIVERY SYSTEM Device, ENDOVASCULAR AORTIC REPAIR | PANTHER | 2023 |
| 2023-12-06 | Abbott Laboratories | $1,227 | Research payment | Cash or cash equivalent | MITRACLIP Device, Vascular | Percutaneous MitraClip Device or Surgical Mitral Valve Repair in Patients with PrImary Mitral Regurgitation Who Are Cand | 2023 |
| 2023-12-04 | Medtronic, Inc. | $8,150 | Research payment | Cash or cash equivalent | CG FUTURE Device, Heart Valves | HVT PMCF Registry | 2023 |
| 2023-12-04 | ABBVIE INC. | $3,945 | Research payment | Cash or cash equivalent | A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants | 2023 | |
| 2023-12-04 | ABBVIE INC. | $3,013 | Research payment | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to | 2023 |
| 2023-12-04 | ABBVIE INC. | $790 | Research payment | Cash or cash equivalent | CREON Drug, ENDOCRINOLOGY | Study to Evaluate Symptoms of Exocrine Pancreatic Insufficiency in Adult Participants With Cystic Fibrosis or Chronic Pa | 2023 |
| 2023-12-04 | GENZYME CORPORATION | $714 | Research payment | Cash or cash equivalent | ATLAS-PEDS: An Open-label, Multinational Study of Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 1 | 2023 | |
| 2023-12-01 | SEAGEN INC. | $44,079 | Research payment | Cash or cash equivalent | A Phase 2 Multi Cohort, Open Label, Multi-Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin | 2023 | |
| 2023-12-01 | ARGENX US, INC. | $7,764 | Research payment | Cash or cash equivalent | VYVGART Drug, Immunology | Efficacy and Safety Study of Efgartigimod in Adults With Post-COVID-19 POTS | 2023 |
The latest 200 records of 1,682.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Cleveland, OH, county Cuyahoga County, OH, state Ohio; placed by its city name.
| Measure | Place (city or town) Cleveland, OH | County Cuyahoga County, OH | State Ohio |
|---|---|---|---|
| Population B01003 | 366,097 | 1,245,873 | 11,810,293 |
| Population, 2020 census P1 | 372,624 | 1,264,817 | 11,799,448 |
| Median age B01002 | 36.3 | 40.4 | 39.7 |
| Under 18 B01001 | 21.0% | 20.5% | 22.0% |
| 65 and over B01001 | 15.2% | 19.5% | 18.3% |
| Households B11001 | 169,683 | 554,551 | 4,863,191 |
| Foreign born B05002 | 6.3% | 7.7% | 5.2% |
| Median household income B19013 | $40,801 | $64,468 | $71,389 |
| Median family income B19113 | $50,461 | $89,252 | $92,749 |
| Per capita income B19301 | $28,266 | $42,747 | $40,552 |
| Poverty rate B17001 | 30.6% | 16.1% | 13.3% |
| Unemployment rate B23025 | 10.8% | 6.6% | 4.8% |
| Civilian labor force B23025 | 180,027 | 650,577 | 5,994,779 |
| Mean commute (minutes) B08013 | 22.5 | 23.3 | 23.4 |
| Bachelor's degree or higher B15003 | 22.4% | 36.5% | 31.5% |
| Housing units B25001 | 201,141 | 615,331 | 5,292,391 |
| Owner-occupied B25003 | 41.7% | 59.4% | 67.2% |
| Renters B25003 | 58.3% | 40.6% | 32.8% |
| Median home value B25077 | $102,000 | $195,400 | $214,800 |
| Median gross rent B25064 | $945 | $1,060 | $1,034 |
| White, not Hispanic B03002 | 33.7% | 56.5% | 75.8% |
| Black B03002 | 45.1% | 28.5% | 12.0% |
| Hispanic or Latino B03002 | 13.2% | 7.0% | 4.8% |
| Asian B03002 | 2.6% | 3.3% | 2.5% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.1% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Cleveland, OH.
Comments